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Abstract
Background: Multidrug-resistant Escherichia coli and other enteric bacteria producing extended-spectrum β-lactamases
(ESBL) have emerged as an important cause of invasive infection. Targeting the primary (intestinal) niche by
decolonization may be a valuable approach to decrease the risk of relapsing infections and to reduce
transmission of ESBL-producing enteric pathogens.
Methods: In a retrospective observational study we evaluated the efficacy of intestinal decolonization treatment using
orally administered colistin or other non-absorbable agents given for 2 to 4 weeks in adult patients with
previous relapsing infection and persistent intestinal colonization with ESBL-positive Enterobacteriaceae (ESBL-E).
Eradication success was defined as negative rectal swab or stool culture at the end of treatment and at
follow up-2 weeks after treatment discontinuation.
Results: First-line decolonization treatment led to eradication of ESBL-E in 19/45 patients (42 %, 7/18 low-dose
[4 × 1 million units] colistin, 3/12 high-dose [4 × 2 million units] colistin, 9/15 rifaximin [2 × 400 mg]), and secondary/
salvage treatment was successful in 8/13 patients (62 %, 20 treatment episodes). Late follow-up showed that
7/13 patients (54 %) with successful initial or salvage decolonization became recolonized within 3 months
after post-treatment assessment while all eight of the patients failing initial or salvage decolonization
treatment with late follow-up remained colonized. A narrative review of the literature confirms the limited
efficacy of non-absorbable antibiotics including conventional selective digestive tract decolonization (SDD)-like
combination regimens for eradicating multidrug-resistant enteric bacteria from the intestinal tract.
Conclusions: At present, there is no clear evidence of a significant decolonization efficacy using single-drug treatment
with oral non-absorbable antibiotics. More effective regimens are needed and a better definition of at risk patients is
required for planning meaningful randomized controlled studies in this field.
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Background
Extended-spectrum β-lactamase (ESBL)-producing gram-
negative Enterobacteriaceae (ESBL-E) are emerging
pathogens [1]. The incidence of infection due to such
microorganisms has been increasing substantially over
the last years [2]. Treatment options in severe infection
are limited, and many infectious diseases practitioners and
medical microbiologists are concerned about the resulting
overuse of carbapenems exerting a selection pressure
leading to the emergence of carbapenemase-producing
microorganisms [3, 4].
Patients with infection due to ESBL-E and other en-
teric bacteria resistant to third-generation cephalospo-
rins are usually colonized by these bacteria in the
intestinal tract. Spontaneous loss of ESBL-positive colo-
nizers does occur, but is substantially delayed in case of
repeated hospitalizations and antibiotic therapies [5].
Regimens for decolonization of ESBL-E in the intestinal
tract have been proposed. The experience with such re-
gimes, however, is limited, and the evidence for their ef-
ficacy comes from few studies most of which are
observational. It is unknown which regimen is best
suited and best tolerated, what is the optimum dose and
the minimum treatment duration to ensure sustained
eradication and not only suppression of the ESBL-
positive organisms in the gut. On the other hand there is
vast experience with and substantial clinical trial data for
so-called selective digestive tract decolonization (SDD)
regimens in intensive care patients and in neutropenic
cancer patients in whom preventive treatment with non-
absorbable drugs like colistin plus tobramycin can de-
crease the risk of infection due to gram-negative enteric
bacteria [6]. In addition, other nonabsorbable drugs like
rifaximin have been used successfully for suppression of
pathogenic or potentially pathogenic enteric bacteria and
thereby may yield clinically beneficial effects in travellers’
diarrhea, hepatic encephalopathy and Crohn´s disease [7].
We started to offer individualized management to
patients with a history of repeated infection due to
ESBL-E. Patients with documented relapsing infection
referred to our specialized outpatient clinic were
screened for intestinal tract colonization with ESBL-E
and if positive and remaining at risk for infection were
offered decolonization treatment with oral colistin or al-
ternative regimens. Initially this programme was of-
fered as an infection control quality improvement
programme to renal transplant patients but subse-
quently was open to other patients with relapsing in-
fection due to cephalosporin-resistant enteric bacteria.
In the present paper we summarize our experience
with intestinal ESBL-E decolonization regimens in 45 pa-
tients given either colistin or rifaximin as first-line regi-
men and a variety of salvage treatments in case of failure.
We discuss the results in the light of other similar data
from the literature that show limited efficacy of current
regimens in eradicating multidrug-resistant enteric
bacteria from the intestinal tract.
Methods
Setting, study design and patient eligibility
The University Medical Center Freiburg is a tertiary care
center in Southwestern Germany with 1.500 beds (65.000
inpatient cases per year) and 550.000 outpatient visits per
year. The study was conducted in accordance with the
standards set by the Declaration of Helsinki and the
research guidelines of the University of Freiburg. We did a
retrospective analysis of patients transferred between
November 2008 and September 2012 to our infectious dis-
eases outpatient department because of relapsing infection
due to ESBL-E for advice on options for prevention of fur-
ther infections. The patients with a history of at least two
invasive ESBL-E infections [urinary tract infection, blood-
stream infection, wound infection, respiratory tract infec-
tion or other sites] within the last year were screened for
persistent colonization by ESBL-E by culture of rectal
swabs and/or fecal samples, urine and other specimens de-
pending on information on previous sites of colonization
or infection. Patients with continued intestinal colonization
by ESBL-positive bacteria resistant to fluoroquinolones and
trimethoprim-sulfamethoxazole or who were intolerant to
these drugs were offered individualized treatment with
nonabsorbable antibiotics as a decolonization trial. All pa-
tients gave verbal or written informed consent before treat-
ment. The local ethics committee (Ethical Committee of
the University of Freiburg Medical Center) approved this
retrospective analysis of patient outcomes.
Decolonization treatment
Regimens initially consisted of oral colistin 4 × 1 million
units daily for 4 weeks. After the impression of poor
results with this regimen, we decided to increase the co-
listin dose to 4 × 2 million units daily (for 4 weeks)
(“high-dose”) or to prescribe an alternative initial regi-
men of rifaximin (2 × 400 mg daily for 2 to 3 weeks) on
the discretion of the infectious disease physician in
charge.
Patients with positive urine cultures were given add-
itional treatment with oral fosfomycin (3 g single-dose),
nitrofurantoin (2 × 100 mg daily for 5 days), or with cefpo-
doxime (2 × 100 mg daily) plus amoxicillin-clavulanic acid
(2 × 875/125 mg daily) or a carbapenem (renal-function
adjusted dose, for 3 to 7 days).
Patient follow-up and definition of success
The patients were asked to present for follow-up
12–16 days (colistin) or 5–10 days (rifaximin) after
treatment initiation, at the end of treatment and
2 weeks after treatment discontinuation. Follow-up
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investigations included a physical work-up, assessment of
tolerance and possible adverse events, a rectal swab for
ESBL-E and additional clinical specimens for culture if
other sites had been positive before. For the purpose of this
analysis decolonization success was defined as negative cul-
tures from rectal swabs or stool at the end of therapy and
2 weeks after therapy discontinuation. Patients without
negative cultures during decolonization treatment were
considered “primary failures”. For patients failing, treatment
options were a repeated course of the initially prescribed
regimen or a change to oral paromomycin (3 × 500 mg
daily), rifaximin (dosage and duration as above), or watch
and wait. During further (late) follow-up (>3 months after
the last 2-week post-treatment assessment) cases were ana-
lysed for new cultures positive for ESBL-E by assessing
microbiology reports in the hospital clinical information
system.
Microbiology
Clinical specimens and rectal swabs were processed at
the local microbiology department in accordance with
“Microbiology Procedures Quality Standards (MiQ)” is-
sued by the German Society for Hygiene and Microbiol-
ogy. ChromID ESBL (BioMérieux, Lyon, France) was
used as commercially available chromogenic screening
medium to detect ESBL-producing Enterobacteriaceae.
The microorganisms were identified by standard microbio-
logical techniques using Vitek 2 (BioMérieux, Germany)
or MALDI-TOF mass spectrometer (Bruker Daltonic,
Germany). Susceptibility testing including confirmatory
tests for ESBL identification were carried out with Vitek 2.
Additional confirmatory tests for ESBL production were
performed using double-disc synergy test using ceftazi-
dime, cefotaxime and cefpodoxime with and without cla-
vulanic acid on Muller Hinton agar supplemented with
cloxacillin where appropriate. Minimal inhibitory concen-
trations (MICs) were determined by gradient diffusion
(Etest, BioMérieux, Germany) according to the manufac-
turer’s instructions. In selected microorganisms additional
MICs of a panel of different drugs were determined by
microdilution tests according to standard protocols and
EUCAST interpretive guidelines.
Statistical analysis
Groups of interest were compared by binomial tests or
Fisher’s exact test as appropriate. A (two-sided) p-value
of <0.05 was considered significant. Analyses were
performed using SPSS Statistics version 20 (SPSS Inc.,
Chicago, IL, USA).
Literature search
A literature search was performed in PubMed (through
January 2015) by using the term (ESBL[All Fields] AND
decolonization[All Fields]) OR (SDD[All Fields] AND
resistance[All Fields]) and by additional handsearching
of original articles.
Results
Patient characteristics and microbiology
A total of 45 patients (out of 55) completed all follow-up
visits and were evaluable for the present analysis. The
median age was 57 years (range, 19 to 86), 20 patients
were male, and 25 patients were female. Many patients
were renal transplant recipients but there was a variety
of other underlying diseases (Table 1). Relapsing infections
in the previous year were primarily urinary tract infections.
The most frequent microorganism was E. coli, followed by
K. pneumoniae (Table 1). Most isolates were resistant
to fluoroquinolones, trimethoprim-sulfamethoxazole and
tetracycline. All were susceptible to carbapenems, and no
or very few E. coli isolates were resistant to fosfomycin
and nitrofurantoin, respectively, while resistance to
gentamicin was observed in 21 E.coli isolates (55 %,
Table 1) and in three of the nine K. pneumoniae iso-
lates (33 %).
Twenty of the 38 E.coli and three of the nine K. pneu-
moniae isolates were retested for MICs in a microdilu-
tion assay. These tests confirmed the results of the
routine susceptibility tests and revealed high rates of re-
sistance in E.coli to streptomycin (MIC >32 μg/mL, 17
isolates [85 %]) and to azithromycin (MIC >16 μg/mL,
all isolates), but low rates of resistance to tigecycline
(MIC >0.5 μg/mL, no isolate), to chloramphenicol
(MIC >8 μg/mL, 3 isolates [15 %]), and to paromomycin
(MIC >32 μg/mL, 3 isolates [15 %]). The geometric
mean MIC of rifaximin was 64 μg/mL (range, 16–
128 μg/mL), and the geometric mean MIC of colistin
was 0.5 μg/mL (range, 0.125–1 μg/mL), respectively.
The three K. pneumoniae isolates tested for MICs
were resistant to streptomycin, chloramphenicol, tigey-
cline, azithromycin and paromomycin, and, compared
with E.coli, showed higher MICs of colistin (2–4 μg/mL)
but similar MICs of rifaximin (64–128 μg/mL) (data not
shown).
Outcomes of initial treatment
Successful decolonization after initial treatment was
observed in 19 patients (42 %, 95 % confidence inter-
val 23–56 %). Treatment with colistin in either dosage
yielded lower rates than rifaximin (low-dose colistin,
7/18 [39 %]; high-dose colistin, 3/12 [25 %]; rifaximin,
9/15 [60 %]), but the differences were not statistically
significant. Patients with successful decolonization
were slightly younger, had more often malignancies as
underlying disease but less often obstructive uropathy
and needed less often additional antibiotics for treatment
of urinary tract infection or bladder colonization (Table 1).
Moreover, the microorganisms showed slightly higher
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rates of resistance to some of the tested drugs in patients
with treatment failures (Table 1), but all these differences
were statistically not significant.
Among the 26 patients without successful decolonization,
nine were considered primary failures (18 % of all, 95 %
confidence interval 8–32 %) while the other 17 patients
Table 1 Clinical and microbiological characteristics of 45 patients according to first-line decolonization results
Parameter Total Decolonization success Decolonization failure
(n = 45) (n = 19) (n = 26)
Median age (range), yrs 57 (19–86) 56 (19–84) 60 (20–86)
Male, n (%) 20 (44 %) 9 (47 %) 11 (42 %)
Underlying diseases, n (%)
▪ Renal transplant 12 (27 %) 5 (26 %) 7 (27 %)
▪ Other solid organ transplant 1 (2 %) 1 (5 %) -
▪ Autoimmune/collagen vascular disease 4 (9 %) 1 (5 %) 3 (12 %)
▪ Obstructive uropathy 16 (36 %) 5 (26 %) 11 (42 %)
▪ Nephrolithiasis 1 (2 %) 1 (5 %) -
▪ Lymphoma or cancer 6 (13 %) 4 (21 %) 2 (8 %)
▪ CVID 2 (4 %) 1 (5 %) 1 (4 %)
▪ Other 11 (24 %) 4 (21 %) 7 (27 %)
Previous infections, n (%)
▪ Urinary tract infection 38 (84 %) 16 (84 %) 22 (85 %)
▪ Bloodstream 9 (20 %) 4 (21 %) 5 (19 %)
▪ Wound infection 5 (11 %) 3 (16 %) 2 (8 %)
▪ Respiratory tract infection 2 (4 %) 1 (5 %) 1 (4 %)
▪ other sites 2 (4 %) 1 (5 %) 1 (4 %)
Microorganisms, n (%)
▪ E.coli 29 (64 %) 11 (58 %) 18 (69 %)
▪ E.coli plus other 9 (20 %) 5 (26 %) 4 (15 %)
▪ Klebsiella pneumoniae 6 (13 %) 2 (11 %) 4 (15 %)
▪ Enterobacter aerogenes 1 (2 %) 1 (5 %) -
In vitro resistance (E.coli) (n = 38), n (%)
▪ Ciprofloxacin 33 (87 %) 13 (81 %) 20 (91 %)
▪ Trimethoprim-sulfamethoxazole 35 (92 %) 14 (88 %) 21 (95 %)
▪ Gentamicin 21 (55 %) 7 (50 %) 14 (64 %)
▪ Tetracycline 33 (87 %) 14 (88 %) 19 (86 %)
▪ Fosfomycin - - -
▪ Nitrofurantoin 2 (5 %) - 2 (9 %)
Decolonization regimen, n (%)
▪ Colistin 4 × 1 18 (40 %) 7 (37 %) 11 (42 %)
▪ Colistin 4 × 2 12 (27 %) 3 (16 %) 9 (35 %)
▪ Rifaximin 15 (33 %) 9 (47 %) 6 (23 %)
Initial additional UTI treatment, n (%) 26 (58 %) 8 (42 %) 18 (69 %)
▪ Oral fosfomycin 9 (20 %) 2 (11 %) 7 (27 %)
▪ Oral nitrofurantoin 3 (7 %) 1 (5 %) 2 (8 %)
▪ Oral cefpodoxime + amoxi-clav 7 (16 %) 4 (21 %) 3 (12 %)
▪ Parenteral carbapenem 7 (16 %) 1 (5 %) 6 (23 %)
Yrs years, n numbers, CVID common variable immunodeficiency syndrome, UTI urinary tract infection, colistin daily dosage given in million units
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with failure had negative cultures during decolonization
but became rapidly positive after treatment discontinuation.
One patient (considered a treatment failure) had initial in-
testinal colonization with E. coli and K. oxytoca and became
negative for E.coli but remained positive for K. oxytoca dur-
ing and after treatment with colistin. The proportions of
patients with primary failures were not different between
the three treatment groups.
Among the organisms cultured from patients with fail-
ure we found one E.coli with a colistin MIC of 2 μg/mL,
possibly indicating development of resistance during
treatment since the original strain was fully susceptible
to colistin but unavailable for retesting and typing. All
other isolates from failures that were available for retest-
ing (n = 11) did not show changes in the MIC of colistin
or rifaximin.
Following treatment, 14 patients in the failure group
(54 %, 95 % confidence interval 35–73 %) versus none in
the success group had positive urine cultures with the
initially colonizing strains, and this appeared to be inde-
pendent of the type of the additional urinary tract infec-
tion (UTI) antibiotics prescribed.
Salvage regimens and late follow-up
A total of 13 patients failing the initial regimen were
subsequently given salvage intestinal decolonization regi-
mens for a total of 20 treatment episodes. Eight of the
patients (62 %, 95 % confidence interval 41–83 %) were
eventually cleared of ESBL-E. After the first salvage regi-
men only 5/13 were successes. Four patients received a
second salvage therapy (one success), and three patients
received a third salvage regimen (two successes). Thus,
when considering initial and salvage regimens, 27/45
patients (60 %, 95 % confidence interval 46–74 %) were
successfully decolonized according to results of early
follow-up swabs (2 weeks post-treatment).
As salvage regimens a variety of regimens were given.
These included colistin (standard dose, four patients;
high-dose, three patients), rifaximin (six patients), or
paromomycin (seven patients). Success rates were 3/7
with colistin (43 %), 3/6 with rifaximin (50 %), and 2/7
with paromomycin (29 %).
According to microbiology records there were 21 cases
with late follow-ups (>3 months after the last 2-week
post-treatment assessment) that included rectal swab
and stool cultures (and other clinical cultures in many
cases). In this subgroup, three out of seven patients
with initially successful intestinal decolonization became
culture-positive during late follow-up (corresponding to
three relapses during 9.4 person years of observation)
while this figure was 3/6 for the patients with initial
failures but successful salvage (three relapses during
7.6 person years) which corresponds to a rate of 7/13
for sustained decolonization (54 %). Of the eight patients
with unsuccessful first salvage regimens all remained or
became positive during late follow-up (covering 4.8 person
years) although some had intermittently been negative
(including one success after second salvage).
Review of the literature
The initial search using the indicated terms yielded 149
articles, handsearching identified 45 additional articles.
Of the resulting 194 articles that were screened 35 full-
text articles were assessed in detail for eligibility (Fig. 1).
After exclusion of studies that did not allow extraction
of data on ESBL-E or carbapenem-resistent Enterobacte-
riaceae (CR-E) decolonization efficacy, ten articles were
included in the current review. Among these, four pro-
spective studies were identified that primarily aimed to
investigate decolonization of ESBL-E or CR-E. In a ran-
domized, double-blind placebo-controlled trial Huttner
et al. found a transient lower carriage rate of ESBL-E at
day 1 after decolonization using a 10 day regimen of co-
listin and neomycin [8]. However no significant differ-
ence in the primary study endpoint (decolonization rate/
negative rectal swab 4 weeks after the end of treatment)
were observed with successful decolonization in 52 % of
patients with active treatment versus 37 % in the placebo
group. Saidel-Odes et al. described successful CR-E
decolonization in the first week after a 7 day regimen of
colistin plus gentamicin (61 % vs. 16 % in placebo arm)
but, again, this significant effect did not last until the
follow-up at 6 weeks (59 % vs. 33 % in placebo arm) [9].
Oren et al. observed a 44 % efficacy in eradicating CR-E
using colistin and/or gentamicin. This was reported to
be significantly different to the spontaneous eradication
rate, yet the latter was with 7 % very low [10].
Buehlmann et al. investigated ESBL-E decolonization
using a 4 day course of paromomycin in intestinal car-
riage and oral antibiotics in urinary tract colonization
[11]. As >80 % of patients suffered from ESBL-E infec-
tion (with a non-reported intestinal colonization rate)
and more than half of the subjects cleared ESBL-E car-
riage without the specified decolonization protocol (i.e.
by systemic antimicrobial and/or surgical treatment), the
high decolonization success rate of 76 % should be inter-
preted cautiously.
Four SDD studies were identified that reported on
ESBL-E or CR-E decolonization efficacy within subgroup
analyses: Lübbert et al. observed no significant differences
with regard to decolonization rates between patients re-
ceiving 7 days of a colistin and gentamicin-containing
SDD-regimen (59 % SDD group vs. 33 % in control group)
in follow up-cultures after 6 weeks [12]. Using colis-
tin plus tobramycin until intensive care unit (ICU) dis-
charge, Oostdijk et al. found higher decolonization rates for
3rd generation cephalosporin-resistant Enterobacteriaceae
(73 %) and for aminoglycoside-resistant Enterobacteriaceae
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(62 %). However, as patients were not followed up,
this reflects end of treatment efficacy, and no sus-
tained effects were reported [13]. The same holds
true for the studies of Abecassis et al. and of Troché
et al. with ESBL-E clearance under SDD regimens of
54 and 46 % respectively [14, 15].
Finally, two retrospective observational non-SDD stud-
ies were identified. Nitschke et al. describe a high effi-
cacy of azithromycin in shortening the duration of
intestinal shedding of ESBL-positive, shiga-toxin produ-
cing, enteroaggregative E. coli (STEC) O104:H4 [16].
These data are derived from the specific setting of an
STEC outbreak with associated hemolytic uremic syn-
drome in Germany in 2011. With regard to the causative
pathogen and the patients included comparability to the
results of the other studies seems limited. The second
study reported predominantly transient suppression of
ESBL-E after a 5 day course of norfloxacin [17].
A summary of the relevant studies containing in-
formation on included patients, targeted pathogen,
decolonization regimen and efficacy as well as resistance
development is available in Table 2.
Discussion
Apart from representing a major risk factor for invasive
infection [18], carriage of ESBL-E may contribute to
the spread of these multidrug-resistant and difficult-
to-treat bacteria due to person-to-person-transmission
and horizontal transfer of resistance genes to coresiding
intestinal bacteria [19].
Accumulating evidence suggests prolonged intestinal
carriage of ESBL-E. Follow-up of healthy travelers that
were colonized with ESBL-E after their return revealed
that only about half (54 %) of travelers cleared
colonization within 2 months and at least 18 % of trav-
elers remained colonized at reevaluation after 6 months
(8 % of patients were lost to follow-up) [20]. Several
studies reported persistent colonization of ESBL-E or
CR-E after hospital discharge or at readmission in 60–90 %
of patients after three months and 25–40 % after 12 months
with repeated hospitalizations, transfer from other health
care facilities, antibiotic (re)exposure and history of
invasive disease (in contrast to detection in surveillance
cultures only) extending the duration of colonization
[5, 21–23].
The experience with intestinal decolonization in
patients carrying ESBL-positive bacteria is limited. We
and others argued that previous studies with SDD in in-
tensive care and cancer patients can be regarded as
proof-of-principle for the efficacy to prevent infection by
topical decolonization or at least suppression of poten-
tially pathogenic enteric bacteria. In fact, as shown in
our review several investigators have published their ex-
perience with classical SDD or similar regimens in eradi-
cating ESBL-E or CR-E from the intestinal tract.
Decolonization efficacy in most of those studies was in
Fig. 1 Flow diagram of literature search. ESBL-E extended-spectrum β-lactamase-producing Enterobacteriaceae, CR-E carbapenem-resistent
Enterobacteriaceae, SDD selective digestive tract decolonization
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Table 2 Identified studies in the context of ESBL-E or CR-E decolonization
Author, year;
study type
Patients included Pathogen Decolonization regimena [duration] Decolonization efficacy
















Colistin 1,26 MU, neomycin
250 mg [10d] (plus nitrofurantoin
3 × 100 mg/d [5d] in urinary tract
colonization) (n = 27) vs. placebo
(n = 27)
52 % vs. 37 %; no significant
difference [≥1 neg. rectal swab
culture]




colonization 50 % at
baseline; systemic
antibiotic treatment in
4 % of patients (vs. 19 %
in placebo group)




Hospitalized carriers (n= 152),





Colistin 2,5 MU (n = 16) or
gentamicin 80 mg (n = 26) or
combination (n = 8) [until
decolonization, max. 60 d] vs.
spontaneous eradication (n = 102)
44 % (42 %, 50 %, 37.5 %) vs.
7 %; significant difference
[3 neg. consecutive rectal
swabs cultures, neg. PCR










treatment in ~40 % of






Hospitalized carriers (n = 40) CR-E (K.
pneumoniae)
Colistin 1 MU, gentamicin 80 mg,
plus SOD [7d] (n = 20) vs. placebo
(n = 20)
59 % vs. 33 %; no significant
difference [neg. rectal swab
culture]





Efficacy 61 % vs. 16 % at
week 2; no impact on
extraintestinal
colonization (groin





Infected patients (n = 83) or





Paromomycin 1 g (intestinal
colonisation) [4d], diverse oral
antibiotics (urinary tract
colonization) [5d], chlorhexidine
mouth rinse [5d] (n = 39) vs.
spontaneous eradication (n = 61)
63 % (ITT analysis)/83 % (on
treatment analysis) vs. 55 %
[≥1 neg. throat and rectal
swab and neg. urine culture]
Median f/u
24 months





SDD studies with ESBL-E or CR-E decolonization efficacy subgroup analysis or retrospective observational studies




Hospitalized carriers (n = 52)
or infected patients (n = 38)
CR-E (K.
pneumoniae)
Colistin 1 MU, gentamicin 80 mg
plus SOD [7d] (n = 14) vs. non
SDD-control (n = 76)
43 % vs. 30 %; no significant
difference [≥3 consecutive
negative rectal swab PCRs













treatment in 43 % of SDD












Colistin 2,5 MU, tobramycin 80 mg,
amphotericin B 500 mg plus SOD
[until discharge]; no control group
73 % in 3CR-E (vs. 80 % in
cephalosporin-sensitive isolates),
62 % in AGR-E(vs. 81 % in
aminoglycoside-sensitive












5 days in 3CR-E, 5.5 days








carriers (n = 28) or infected
patients (n = 11)
ESBL-E Colistin, tobramycin, parenteral
cefotaxime [until ICU discharge,
dose and duration not specified];
no control group
Overall 54 % (21/39), with
follow-up 21/27 (78 %)






In 9/23 patients with
tobramycin-resistent
isolates decolonization






















(n = 27) or infected
patients (n = 10)
ESBL-E Colistin 1.5 MU plus neomycin
500 mg or plus erythromycin
500 mg [until two negative
rectal swabs or ICU discharge];
no control group












carriage of STEC with
or without HUS (n = 65)
STEC O104:H4 Azithromycin [cumulative 3 g in
14 days] (n = 22) vs. spontaneous
eradication (n = 43)
95 % vs. 19 %; significant
difference [≥2 neg. stool





n.d. Subsequently, 15 long
term STEC carriers were
treated with 3 days






Hospitalized carriers (n = 7)
or infected patients (n = 2)
ESBL-E
(E. coli 67 %,
K. pneumoniae
33 %)
Norfloxacin 2 × 400 mg/d [5d];
no control group
44 % [≥1 neg. stool culture] 28 days n.d. Transient ESBL-E
suppression at day
2–3 after completion
of norfloxacin in 9/9
patients
ESBL-E extended-spectrum β-lactamase-producing Enterobacteriaceae, CR-E carbapenem-resistent Enterobacteriaceae, 3CR-E 3rd generation cephalosporin-resistant Enterobacteriaceae, AGR-E aminoglycoside-resistant
Enterobacteriaceae, STEC O104:H4 shiga toxin–producing enteroaggregative Escherichia coli, HUS hemolytic uremic syndrome, ICU intensive care unit, n numbers, n.d. not determined, neg. negative, SDD selective digest-
ive tract decolonization, SOD selective oral decontamination, MU million units, f/u follow-up, MIC minimal inhibitory concentration
aDecolonization regimens were applied four times daily via oral route or nasogastric tube unless otherwise stated as dose per day (/d). bResistance against ceftazidime, cefotaxime and ceftriaxone were considered as













the range of 40–50 % - whether this is significantly
higher than the spontaneous eradication rate and a
‘watch and wait’ strategy cannot be answered by available
data. Interpretation of the published series is particularly
hampered by diverse (often very short) follow-up pe-
riods, different definitions of decolonization success and
detection methods (additional methodological heteroge-
neities are summarized in Table 3).
Of the four prospective studies two were randomized,
double-blind, placebo-controlled trials. Both failed to
demonstrate a significant difference in decolonization ef-
ficacy after 4–6 weeks using colistin in combination with
an aminoglycoside when compared to placebo [8, 9].
Given the limited efficacy in the outlined studies and an
increasing prevalence of aminoglycoside-resistance in
Enterobacteriaceae, gentamicin, neomycin or tobramycin
may no longer be the first choice of drugs for most
promising decolonization regimens.
In our own experience different single-drug
decolonization regimens were successful after a first
decolonization course in 42 % of patients. Adding
those patients who were successfully decolonized
after a secondary/salvage regimen yielded an overall
decolonization efficacy of 60 % in short-term follow-up.
However, the recolonization rate of 46 % in the subgroup
with available follow-up data points to a substantial
proportion of patients with only temporarily negative rec-
tal swab cultures. There are several explanations for this.
Either the decolonization regimen lead to suppression of
the ESBL-producing bacteria in the intestinal tract below
the detection limit of the cultural method used rather than
to true eradication (and renewed selection pressure due to
reapplication of antimicrobial therapy in often highly
comorbid patients drives ‘outgrowth’ of ESBL-E). Or
the primarily successful intestinal decolonization was
followed by endogenous recolonization from extrain-
testinal sites or exogenous recolonization from the
family, hospital environment or contaminated food.
Molecular methods for strain detection and typing are
needed to address this important question.
When considering patients with late follow-up
(>3.5 months after completion of the decolonization
regimen) a sustained decolonization success was achieved
in 54 %. This proportion is in the range of the above
mentioned spontaneous ESBL-E clearance rate of healthy
individuals, yet it may be higher than the spontaneous
decolonization rate in a control group of patients with
high comorbidity and repeated readmissions and still an
attractive level for patients at high risk to develop symp-
tomatic and potentially severe infection.
Whereas colistin and paromomycin have been used in
diverse SDD regimens the present study is the first to in-
vestigate the impact of rifaximin in decolonization regi-
mens. The rationale for using rifaximin were the low
rates of resistance of ESBL-E along with its favourable
pharmacological profile with negligible intestinal absorp-
tion yielding intraluminal or fecal rifaximin concentra-
tions that are 50 to 500-fold higher than the MICs of
Enterobacteriaceae [24]. Decolonization efficacy of the
first line regimen tended to be higher with rifaximin
compared to colistin high- or low-dose (60 % vs. 25 % or
39 %) – owing to the small number of patients included
the difference proved not to be statistically significant.
The current study bears the limitations of a retrospect-
ive, non-randomized study with a small sample size not
allowing for firm conclusions on decolonization efficacy.
However, it is one of the very few studies that addresses
specific ESBL-E decolonization strategies. In addition, by
including a brief review of the existing literature/studies
we wanted to highlight the methodological challenges
and caveats in further studies. Another limitation is that
organisms isolated from patients with failures were not
systematically retested to fully assess the emergence of
resistance or of non-susceptibility to decolonization and
unrelated drugs. It needs to be borne in mind, however,
that there are no susceptibility and resistance break-
points for decolonization, and pre-decolonization sus-
ceptibility test results for colistin using established
breakpoints, obviously, were not predictive of failure.
We speculate that additional testing at high inocula and
Table 3 Methodological heterogeneities in previous studies
and open questions for future decolonization studies
Methodological heterogeneities in previous studies
▪ Different ESBL-E sampling (perianal vs. rectal swab vs. fecal sample)
and detection (culture vs. PCR-based technology vs. combined)
▪ Diverse definitions of decolonization success (number of negative
samples, duration of follow-up period)
▪ In- or exclusion of patients with concomitant ESBL-E infection
▪ Intestinal decolonization with or without systemic antibiotic treatment
▪ Availability of pre-decolonization antibiotic susceptibility tests and
variable impact on decolonization regimen
Open questions that need to be addressed in future studies
▪ Are there effective decolonization strategies leading to sustained
clearance of ESBL-E?
▪ What is the optimal regimen (combination regimen?), dose and duration?
▪ Will we observe resistance development (and risk to lose important
last resort antibiotics e.g. colistin)?
▪ Which patients may have the greatest benefit of decolonization?
▪ What is the impact of extraintestinal colonization (perianal region,
groin)? Should decolonization strategies address this?
▪ Does relapse represent intestinal ‘outgrowth’ of suppressed ESBL-E or
re-colonization from extraintestinal sites or other patients, food sources
or the environment?
▪ Do pathogens differ with respect to the decolonization success rate
(e.g. Klebsiella spp. vs. Escherichia coli vs. Enterobacter spp.)?
▪ How robust is the intestinal microbiome under antibiotic treatment?
What is its impact on ESBL-E colonization resistance?
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for bactericidal activity will be needed to better discrim-
inate susceptibility versus resistance specific to intestinal
decolonization. Moreover, as molecular typing of isolates
of patients that failed decolonization was not performed
within this study, the question of clonal diversity i.e. ex-
ogenous ESBL-E reacquisition rather than persistence
under decolonization treatment remained unresolved.
Finally, we used a single rectal swab followed by conven-
tional culture in chromogenic screening medium to de-
tect persistent intestinal ESBL-E colonization at the time
of therapy initiation which may have been too insensitive
or resulted in a selection bias favoring the inclusion of
patients with high titers of ESBL-E. There is controversy
about which method – repeated rectal swab cultures, the
use of fecal samples, PCR-based detection methods – is
best suited and most reliable for the detection of intestinal
tract ESBL-E colonization [25–27]. Although the signifi-
cance of ESBL-E carriage below the detection limit of the
applied methodology is unclear, ESBL-E persistence in
very low density after decolonization treatment needs to
be taken into consideration.
Among the identified prerequisites for future trials we
think are stringent definitions of decolonization success
with long follow-up periods, reliable and sensitive sam-
pling and detection techniques, a distinction between
colonized and infected patients and between intestinal
and extraintestinal colonization. Important aspects like
resistance development of Enterobacteriaceae under pro-
longed decolonization treatment, achievability of sus-
tained decolonization, identification of ESBL-E colonized
patients that are at greatest risk of infection and the im-
pact of the intestinal microbiome need to be addressed
in future studies (for a detailed list see Table 3). It is only
then we may be able to answer the whole range of ques-
tions that arise in the field of decolonization strategies.
Conclusions
We conclude that the observed limited efficacy of the
decolonization regimen taken together with the hetero-
geneity of previous studies with respect to methodology
as well as interventional strategies underlines the need
for randomized controlled studies in this field of emi-
nent importance for infectious diseases and for the
whole medical science.
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